Congress

← vista completa

Published on June 1, 2003 | http://doi.org/10.5867/medwave.2003.05.915

Quimioterapia en tumores del sistema nervioso central

Quimioterapia en tumores del sistema nervioso central

David Reardon

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

David Reardon

Duke University, Carolina del Norte, Estados Unidos

Figures

Article has no figures.

Forum

No messages

History

Citation Reardon D. Quimioterapia en tumores del sistema nervioso central. Medwave 2003;3(05):e915 doi: 10.5867/medwave.2003.05.915

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/06/2003

Index

Metrics

Not available at the moment.

Notes

References

  1. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002 Mar 1;20(5):1383-8. | CrossRef | PubMed
  2. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001 Aug;7(8):2309-17 | PubMed
  3. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000 Oct 15;18(20):3522-8. | PubMed
  4. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002 May 1;20(9):2277-83. | CrossRef | PubMed